Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Blood Cancer JournalThe treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies and optimized supportive care. However, the attrition rate (AR), defined as the proportion of patients who die without advancing to ...
Luis Gerardo Rodríguez-Lobato +12 more
doaj +1 more source
Multiple Myeloma : an update on disease biology and therapy [PDF]
, 2004 Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Cook, Rachel J., Dingli, David
core
Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]
, 2017 Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana +5 more
core +1 more source
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Frontiers in Immunology, 2018 Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years.
Yu-Tzu Tai +4 more
doaj +1 more source
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. [PDF]
, 2016 Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes.
Amer Beitinjaneh +56 more
core +2 more sources
Acute kidney injury on chronic kidney disease: From congestive heart failure to light chain deposition disease and cast nephropathy in multiple myeloma [PDF]
, 2019 Acute on chronic renal failure is a common but notably broad diagnosis. We present a 64-year-old man with a history of diastolic heart failure and chronic kidney disease, admitted for an elevated creatinine.
Cheng, Steven +3 more
core +1 more source
Gene Co-expression Network and Copy Number Variation Analyses Identify Transcription Factors Associated With Multiple Myeloma Progression [PDF]
, 2019 Multiple myeloma (MM) has two clinical precursor stages of disease: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the mechanism of progression is not well understood.
Abu Zaid, Mohammad +7 more
core +5 more sources
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Nature Communications, 2020 CD229 is expressed on the surface of multiple myeloma cells, as well as B and T lymphocytes. Here, the authors engineer CD229-specific CAR T cells and, using patient samples and mouse models, show that treatment with these cells reduces tumour burden and
Sabarinath V. Radhakrishnan +13 more
doaj +1 more source
Haematologica, 2023 Multiple myeloma (MM) is an incurable disease of the bone marrow (BM) characterized by the uncontrolled proliferation of neoplastic plasma cells. While CD8+ T cells have an established role in disease control, few studies have focused on these cells ...
James Favaloro +10 more
doaj +1 more source
Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma [PDF]
, 2016 In multiple myeloma, an overabundance of monoclonal plasma cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bone resorption and suppressed bone formation. Matrix-embedded osteocytes comprise more than 95% of
Anderson, Judith +10 more
core +2 more sources